


II. CLAIM AMENDMENTS

1. (Currently Amended) An Substituted Azetidine compound compounds of formula I,



wherein

A represents a -C=O-moiety,

R¹, R³, identical or different, represent a hydrogen atom or a linear or branched, saturated or unsaturated C₁₋₄-aliphatic group,

R² represents a hydroxyl group or a C₁₋₃-alkoxy group,

or R¹ and R² or R² and R³ together form an -O-CH₂-CH₂-moiety, which is optionally substituted with one or more methyl groups

R⁴ represents a hydrogen atom, an optionally at least mono- substituted aryl group, or a linear or branched, saturated or unsaturated aliphatic group, which may be substituted by one or more substituents independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C₁₋₄-alkoxy, branched or unbranched C₁₋₄-perfluoroalkoxy and branched or unbranched C₁₋₄-perfluoroalkyl,

R⁵ represents a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group,

R⁶ represents a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group,

with the provisos

that if R² is alkoxy, at least one of R¹, R³, R⁴, R⁵ And R⁶ does not represent a hydrogen atom,

that if R⁴ represents a hydrogen atom and one of the residues R⁵ and R⁶ represents a hydrogen atom, then the other one of these residues R⁵ and R⁶ does not represent a methyl group, which is substituted by an -NH₂-moiety or an azaheterocycle, and

optionally in form of one of the stereoisomers, a racemate or in form of a mixture of at least two of the stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

2. (Currently Amended) A compound ~~Compounds~~ according to claim 1, characterized in that R¹ and R³, identical or different, represent a hydrogen atom or a linear or branched C₁₋₄-alkyl group.

3. (Currently Amended) A compound ~~Compounds~~ according to claim 1, characterized in that R¹ and R³ are identical and represent a C₁₋₄- alkyl group.

4. (Currently Amended) A compound ~~Compounds~~ according to claim 1, characterized in that R² represents a hydroxyl group or a methoxy group.

5. (Currently Amended) A compound ~~Compounds~~ according to claim 1, characterized in that R⁴ represents a hydrogen atom, an optionally at least mono-substituted phenyl group, or a linear or branched, saturated or unsaturated C₁₋₆ aliphatic group, whereby said aliphatic group may be substituted by one or more substituents independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C₁₋₄- alkoxy, branched or unbranched C₁₋₄-perfluoroalkoxy and branched or


unbranched C₁₋₄-perfluoroalkyl, preferably a hydrogen atom, a methyl group or an unsubstituted phenyl group.

6. (Currently Amended) A compound ~~Compounds~~ according to claim 5, characterized in that R⁵ represents a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched, saturated or unsaturated, optionally at least mono- substituted C₁₋₆ aliphatic group.

7. (Currently Amended) A compound ~~Compounds~~ according to claim 1, characterized in that R⁶ represents a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched, saturated or unsaturated, optionally at least mono- substituted C₁₋₆ aliphatic group.

8. (Withdrawn) Compounds according to claim 1, characterized in that R⁷, R⁸, R⁹, R¹⁰, independent from one another, represent a linear or branched, saturated or unsaturated, optionally at least mono-substituted C₁₋₆ aliphatic group.

9. (Currently Amended) A compound ~~Compounds~~ according to claim 1 of formula I,



wherein

A represents a -C=O-moiety,

R¹, R³ both identically represent an iso-propyl group or a tert-butyl group,

R² represents a hydroxyl group or a methoxy group,

or R¹ and R² or R² and R³ together form an -Q-CH₂-C(CH₃)₂-chain, whereby the oxygen atom of said chain is bonded to the 4- position of the phenyl ring,

R⁴ represents a hydrogen atom, a methyl group or an unsubstituted phenyl group,

R⁵ represents a bromine atom, or a hydroxyl group,

R⁶ represent a hydrogen atom, a methyl group or a hydroxyl group,

optionally in form of one of the stereoisomers, a racemate or in form of a mixture of at least two of the stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

10. (Currently Amended) A compound ~~Compounds~~ according to claim 1 selected from the group consisting of

[1] (3,5-di-tert-butyl-4-hydroxy-phenyl)-(3-hydroxy- azetidin-1-yl)-methanone;

[3] (3,5-di-tert-butyl-4-hydroxy-phenyl)-(3-hydroxy-3- methyl-azetidin-1-yl)-methanone;

[4] (3,5-di-tert-butyl-4-hydroxy-phenyl)-(3-hydroxy-2- methyl-azetidin-1-yl)-methanone;

[7] (3-Bromo-azetidin-1-yl)-(3,S-di-tert-butyl-4-hydroxy- phenyl)-methanone;

[9] (3,5-di-tert-butyl-4-methoxy-phenyl)-(3-hydroxy- azetidin-1-yl)-methanone;


[10] (3-hydroxy-azetidin-1-yl)-(4-hydroxy-3,S-diisopropyl- phenyl)-methanone;

[12] (3,5-di-tert-butyl-4-hydroxy-phenyl)-(3-hydroxy-2- phenyl-azetidin-1-yl)-methanone;

[14] (7-tert-butyl-3,3-dimethyl-2-3-dihydro-benzofuran-S- yl)-(3-hydroxy-azetidin-1-yl)-methanone;


optionally in form of a corresponding salt or a corresponding solvate.

11. (Currently Amended) Process for the preparation of an substituted azetidine ~~compound~~ compounds of formula I according to ~~of claim 1~~ claim 1, characterized in that at least one compound of formula II,



II

wherein R¹-R³ have the meaning according to claim 1 ~~claim 1~~, X represents a bond and R represents a carboxy group or an activated carbonyl group, is reacted with at least one compound of formula III,



III

optionally in the form of a corresponding salt, wherein R⁴-R⁶ have the meaning according to claim 1, to yield a compound of formula I according to claim 1, wherein A represents a -(C=O)-moiety which is optionally purified and/or optionally isolated.

12. (Currently Amended) Medicament comprising at least one ~~substituted~~ azetidine compound according to ~~of claim 1~~ claim 1 and one or more pharmaceutically acceptable excipients.

13. (Currently Amended) A method for the ~~prophylaxis and/or~~ treatment of cyclooxygenase-1 or cyclooxygenase-2 related disorders comprising administering to a patient in need thereof a cyclooxygenase-1 or cyclooxygenase-2 inhibiting amount of the medicament according to claim 12.

14. (Cancelled)

15. (Currently Amended) A method for the ~~prophylaxis and/or~~ treatment of pain comprising administering to a patient in need thereof a pain inhibiting amount of the medicament according to claim 12.

16. (Currently Amended) A method for the ~~prophylaxis and/or~~ treatment of inflammation comprising administering to a patient in need thereof an inflammation inhibiting amount of the medicament according to claim 12.

17. (Currently Amended) A method for the ~~prophylaxis and/or~~ treatment of inflammation according to claim 16 where the inflammation is the result of a disorder selected from the group consisting of arthritis, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis, rheumatic fever, symptoms associated with ~~influenza or other viral infections, common cold~~, lower back pain, neck pain, dysmenorrhea, headache, toothache, sprains, strains, myositis, neuralgia, synovitis, gout, ankylosing spondylitis, bursitis, edema, ~~inflammations following dental procedures, inflammations following dental procedures, vascular diseases~~, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, ~~Hodkin's disease~~, sclerodoma, ~~type I diabetes~~, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, ~~swelling occurring after injury~~ and myocardia ischemia.

18-22. (Cancelled)

23. (Currently Amended) A compound ~~Compounds~~ according to claim 1 where the stereoisomers are enantiomers or diastereomers.

24. (Currently Amended) A compound ~~Compounds~~ of claim 3 where the C₁₋₄- alkyl group, is a C₃₋₄ alkyl group.

25. (Currently Amended) A compound ~~Compounds~~ of claim 3 where a C₁₋₄- alkyl group, is an iso-propyl group or a tert.-Butyl group.

26. (Currently Amended) A compound ~~Compounds~~ of claim 1 where R⁶ represents a hydrogen atom, a hydroxyl group or a methyl group.

27. (Currently Amended) A compound ~~Compounds~~ according to claim 1, characterized in that R⁷, R⁸, R⁹, R¹⁰, independent from one another, represent a -linear or branched C₁₋₆ alkyl group.

28-35. (Cancelled)

36. (Currently Amended) A medicament comprising at least one ~~substituted~~ azetidine compound according to claim 2 and one or more pharmaceutically acceptable excipients.

37. (Currently Amended) A medicament comprising at least one ~~substituted~~ azetidine compound according to claim 3 and one or more pharmaceutically acceptable excipients.


38. (Currently Amended) A medicament comprising at least one ~~substituted~~ azetidine compound according to claim 4 and one or more pharmaceutically acceptable excipients.

39. (Currently Amended) A medicament comprising at least one ~~substituted~~ azetidine compound according to claim 5 and one or more pharmaceutically acceptable excipients.

40. (Currently Amended) A medicament comprising at least one ~~substituted~~ azetidine compound according to claim 6 and one or more pharmaceutically acceptable excipients.

41. (Currently Amended) A medicament comprising at least one ~~substituted~~ azetidine compound according to claim 7 and one or more pharmaceutically acceptable excipients.

42. (Currently Amended) A medicament comprising one or more pharmacologically acceptable excipients and at least one substituted azetidine compound of formula I,



wherein

A represents a -C=O-moiety,

R¹, R³, identical or different, represent a hydrogen atom or a linear or branched, saturated or unsaturated C₁₋₄-aliphatic group,

R² represents a hydroxyl group or a C₁₋₃-alkoxy group,

or R¹ and R² or R² and R³ together form an -O-CH₂-CH₂-moiety, which is optionally substituted with one or more methyl groups,

R⁴ represents a hydrogen atom, an optionally at least mono- substituted aryl group, or a linear or branched, saturated or unsaturated aliphatic group, which may be substituted by one or more substituents independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C₁₋₄-alkoxy, branched or unbranched C₁₋₄-perfluoroalkoxy and branched or unbranched C₁₋₄-perfluoroalkyl,

R⁵ represents a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group,

R^6 represents a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group with the provisos

that if R^4 represents a hydrogen atom and one of the residues R^5 and R^6 represents a hydrogen atom, then the other one of these residues R^5 and R^6 does not represent a methyl group, which is substituted by an $-NH_2$ -moiety or an azaheterocycle, and

optionally in form of one of the stereoisomers, a racemate or in form of a mixture of at least two of the stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.